Globalization is increasingly an imperative for Chinese biopharmas with 95% of respondents either conducted or expressed interest in ex-China clinical trials
Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report · page 40 of 58
Survey data from IQVIA/L.E.K. Consulting (N=56).
Consulting deck · market_landscape · quantify_impact · dense density
Slide locked Sign in to view
Slide schematic 5/5
chart 1/1 list 1/1 source-note 1/1 title 2/2
Components 5
bar-stacked bullet source-note action-title headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 1
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.